Baltimore, MD, United States of America

Karen Lammers


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Karen Lammers

Introduction

Karen Lammers is a notable inventor based in Baltimore, MD, who has made significant contributions to the field of medical research. Her work primarily focuses on the modulation of CXCR3 signaling, which has implications for various autoimmune diseases. With one patent to her name, Lammers is recognized for her innovative approach to addressing health issues related to gluten and autoimmunity.

Latest Patents

Lammers holds a patent titled "Methods for screening for modulators of CXCR3 signaling." This patent identifies CXCR3 as a physiological receptor for gliadin, a component of gluten. The patent outlines assays for determining modulators of CXCR3 signaling and highlights fragments of gliadin that function as inhibitors of this signaling pathway. Furthermore, it provides methods for treating diseases associated with gluten and autoimmunity, including celiac disease, gluten sensitivity, rheumatoid arthritis, multiple sclerosis, and several others.

Career Highlights

Karen Lammers is affiliated with the University System of Maryland, where she continues her research and development efforts. Her work has the potential to impact the treatment of various autoimmune diseases, making her a valuable asset to the medical research community.

Collaborations

Lammers collaborates with esteemed colleagues such as Alessio Fasano and Ruiliang Lu, who are also prominent figures in the field of gluten-related disorders and autoimmune research.

Conclusion

Karen Lammers exemplifies the spirit of innovation in medical research, particularly in the context of gluten and autoimmune diseases. Her contributions through her patent and collaborations highlight the importance of scientific inquiry in addressing complex health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…